142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

304811
Developing an academic-community partnership to eliminate HPV vaccine disparities in Iowa

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Wednesday, November 19, 2014 : 8:50 AM - 9:10 AM

Briana Woods-Jaeger, PhD , Developmental & Behavioral Sciences, Children's Mercy Hospital, Kansas City, MO
Meagan Schorr, MPH, CHES , Department of Community and Behavioral Health, University of Iowa, Iowa City, IA
Dominica Rehbein, BA , Department of Health Management and Policy, University of Iowa, Iowa City
Barbara Baquero, PhD, MPH , Community and Behavioral Health, University of Iowa, College of Public Health, Iowa City, IA
Jason D. Daniel-Ulloa, PhD, MPH , College of Public Health, Community and Behavioral Health, University of Iowa, Iowa City, IA
Nationally, there are alarming Human Papillomavirus (HPV) vaccination and cervical cancer disparities experienced by African American (AA) women. Diagnosis rates of cervical cancer are nearly twice as high in AA women than white women and associated with higher mortality. In Iowa, AA experience significant cancer disparities, with a diagnosis rate 10% higher than whites and higher mortality rates than any other racial group. Promoting the HPV vaccine among AA mothers and daughters offers one opportunity to reduce cervical cancer disparities and spark dialogue within families about the HPV vaccine in a community impacted by lower overall vaccination rates. To address this, an action committee has formed consisting of faculty in public health, nursing and medicine as well as leaders of community organizations, parents and adolescent young women. Supported by a grant from the Iowa Cancer Consortium, this committee was established to: 1) identify community-driven research priorities related to HPV vaccine disparities, 2) develop long-term collaborative research agendas between community and academic partners, and 3) guide culturally-relevant community activities to provide information related to the HPV vaccine and cervical cancer prevention. We will describe our process of engaging community and academic partners, share themes from our key informant interviews, describe our on-going community engagement activities, and highlight the committee’s current research and action agenda. We will conclude with discussing challenges experienced and lessons learned in engaging in a dynamic, flexible, responsive process and discuss key elements and strategies that can facilitate productive, mutually beneficial academic-community research and action partnerships.

Learning Areas:

Assessment of individual and community needs for health education
Diversity and culture
Implementation of health education strategies, interventions and programs
Planning of health education strategies, interventions, and programs

Learning Objectives:
Explain the process of engaging community and academic partners in an effort to eliminate HPV vaccine disparities in Iowa. Describe key recommendations for research priorities and culturally-relevant community activities to eliminate HPV disparities among African American women. Describe the application of community-based participatory research principles in addressing HPV disparities among African American women.

Keyword(s): Community-Based Research (CBPR), Cancer and Women’s Health

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am an Assistant Professor at the University of Iowa, College of Public Health whose research focuses on adolescent risk behavior prevention and mental health promotion and health equity. I have training and experience in community-based participatory research, and in conducting and supervising evidenced-based youth empowerment and advocacy programs. I have published and presented on these and related topics.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.